Materials Map

Discover the materials research landscape. Find experts, partners, networks.

  • About
  • Privacy Policy
  • Legal Notice
  • Contact

The Materials Map is an open tool for improving networking and interdisciplinary exchange within materials research. It enables cross-database search for cooperation and network partners and discovering of the research landscape.

The dashboard provides detailed information about the selected scientist, e.g. publications. The dashboard can be filtered and shows the relationship to co-authors in different diagrams. In addition, a link is provided to find contact information.

×

Materials Map under construction

The Materials Map is still under development. In its current state, it is only based on one single data source and, thus, incomplete and contains duplicates. We are working on incorporating new open data sources like ORCID to improve the quality and the timeliness of our data. We will update Materials Map as soon as possible and kindly ask for your patience.

To Graph

1.080 Topics available

To Map

977 Locations available

693.932 PEOPLE
693.932 People People

693.932 People

Show results for 693.932 people that are selected by your search filters.

←

Page 1 of 27758

→
←

Page 1 of 0

→
PeopleLocationsStatistics
Naji, M.
  • 2
  • 13
  • 3
  • 2025
Motta, Antonella
  • 8
  • 52
  • 159
  • 2025
Aletan, Dirar
  • 1
  • 1
  • 0
  • 2025
Mohamed, Tarek
  • 1
  • 7
  • 2
  • 2025
Ertürk, Emre
  • 2
  • 3
  • 0
  • 2025
Taccardi, Nicola
  • 9
  • 81
  • 75
  • 2025
Kononenko, Denys
  • 1
  • 8
  • 2
  • 2025
Petrov, R. H.Madrid
  • 46
  • 125
  • 1k
  • 2025
Alshaaer, MazenBrussels
  • 17
  • 31
  • 172
  • 2025
Bih, L.
  • 15
  • 44
  • 145
  • 2025
Casati, R.
  • 31
  • 86
  • 661
  • 2025
Muller, Hermance
  • 1
  • 11
  • 0
  • 2025
Kočí, JanPrague
  • 28
  • 34
  • 209
  • 2025
Šuljagić, Marija
  • 10
  • 33
  • 43
  • 2025
Kalteremidou, Kalliopi-ArtemiBrussels
  • 14
  • 22
  • 158
  • 2025
Azam, Siraj
  • 1
  • 3
  • 2
  • 2025
Ospanova, Alyiya
  • 1
  • 6
  • 0
  • 2025
Blanpain, Bart
  • 568
  • 653
  • 13k
  • 2025
Ali, M. A.
  • 7
  • 75
  • 187
  • 2025
Popa, V.
  • 5
  • 12
  • 45
  • 2025
Rančić, M.
  • 2
  • 13
  • 0
  • 2025
Ollier, Nadège
  • 28
  • 75
  • 239
  • 2025
Azevedo, Nuno Monteiro
  • 4
  • 8
  • 25
  • 2025
Landes, Michael
  • 1
  • 9
  • 2
  • 2025
Rignanese, Gian-Marco
  • 15
  • 98
  • 805
  • 2025

Steffensen, Karina Dahl

  • Google
  • 3
  • 7
  • 62

in Cooperation with on an Cooperation-Score of 37%

Topics

Publications (3/3 displayed)

  • 2019Development of a decision aid to support ovarian cancer patient decide on CA125 biomarker monitoringcitations
  • 2017Biomarker CA125citations
  • 2007Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer62citations

Places of action

Chart of shared publication
Jensen, Pernille Tine
2 / 2 shared
Kargo, Anette
2 / 2 shared
Coulter, Angela
2 / 2 shared
Jakobsen, Anders
1 / 2 shared
Brandslund, Ivan
1 / 2 shared
Jeppesen, Ulla
1 / 1 shared
Waldstrøm, M.
1 / 1 shared
Chart of publication period
2019
2017
2007

Co-Authors (by relevance)

  • Jensen, Pernille Tine
  • Kargo, Anette
  • Coulter, Angela
  • Jakobsen, Anders
  • Brandslund, Ivan
  • Jeppesen, Ulla
  • Waldstrøm, M.
OrganizationsLocationPeople

document

Biomarker CA125

  • Steffensen, Karina Dahl
  • Jensen, Pernille Tine
  • Kargo, Anette
  • Coulter, Angela
Abstract

Background: The majority of patients with ovarian cancer (OC) are diagnosed with advanced disease (70-80 %) and will experience disease relapse with only limited curative potential. Early initiation of relapse treatment based on rising CA125 alone does not improve survival. Increasing CA125 can be detected months before symptoms arise and recurrence is visible on imaging. Therefore, biochemical detection of potential relapse by CA125 assessment can cause significant distress. A decision aid (DA) is a tool that provides information and describes advantages and disadvantages of a specific intervention thereby facilitating patient’s involvement in decision making. The present study develops and validates a DA in decision-making on CA125 monitoring during follow-up after OC treatment.<br/>Methods: Development of the DA was conducted in collaboration with clinicians, patients with OC, representatives from patient organisations and cancer societies. First, a focus group of seven former OC patients was performed followed by a quantitative rating of the DA pilot version. The DA was adapted accordingly and then tested in 14 OC patients with recurrence using a structured interview guide (alpha testing). A final adaptation was done and the DA is now ready for testing on real-time patients (beta test).<br/>Results: The alpha test showed that patients had a good understanding of the information provided in the DA. In total, 10 of the patients indicated that the DA helped clarifying what was important,and 12 patientsagreed that the DA prepared them to make a better decision andhelped themreflecting on their concerns regarding CA125.<br/>Conclusion: The DA was useful in decision making regarding monitoring CA125 during follow up after OC. The majority of participants indicated that the DA was helpful in clarifying their concerns and would be helpful in making a better decision. The effectiveness of the DA will be tested in beta test. <br/>

Topics
  • impedance spectroscopy